Artículos de revistas: "Pulmonary Pathophysiology"

1

Cherniack, Neil S. "Pulmonary Pathophysiology". Annals of Internal Medicine 131, n.º 5 (7 de septiembre de 1999): 399. http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00022.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

2

Gonzalez, Norberto C. "PULMONARY PATHOPHYSIOLOGY". Shock 11, n.º 2 (febrero de 1999): 152. http://dx.doi.org/10.1097/00024382-199902000-00018.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

3

Grippi, Michael A. "PULMONARY PATHOPHYSIOLOGY". Shock 5, n.º 4 (abril de 1996): 311. http://dx.doi.org/10.1097/00024382-199604000-00013.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

4

Chamarthy, Murthy R., Asha Kandathil y Sanjeeva P. Kalva. "Pulmonary vascular pathophysiology". Cardiovascular Diagnosis and Therapy 8, n.º 3 (junio de 2018): 208–13. http://dx.doi.org/10.21037/cdt.2018.01.08.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

5

Gao, Yuansheng y J. Usha Raj. "Pathophysiology of Pulmonary Hypertension". Colloquium Series on Integrated Systems Physiology: From Molecule to Function 9, n.º 6 (22 de noviembre de 2017): i—104. http://dx.doi.org/10.4199/c00158ed1v01y201710isp078.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

6

Angerio, Allan D. y Peter A. Kot. "Pathophysiology of pulmonary edema". Critical Care Nursing Quarterly 17, n.º 3 (noviembre de 1994): 21–26. http://dx.doi.org/10.1097/00002727-199411000-00004.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

7

Higenbottam, Tim. "Pathophysiology of Pulmonary Hypertension". Chest 105, n.º 2 (febrero de 1994): 7S—12S. http://dx.doi.org/10.1378/chest.105.2_supplement.7s.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

8

Klayton, Ronald J. "PULMONARY PATHOPHYSIOLOGY — THE ESSENTIALS". Military Medicine 158, n.º 2 (1 de febrero de 1993): A9. http://dx.doi.org/10.1093/milmed/158.2.a9a.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

9

Shibuya, Kazutoshi, Chikako Hasegawa, Shigeharu Hamatani, Tsutomu Hatori, Tadashi Nagayama, Hiroko Nonaka, Tsunehiro Ando y Megumi Wakayama. "Pathophysiology of pulmonary aspergillosis". Journal of Infection and Chemotherapy 10, n.º 3 (2004): 138–45. http://dx.doi.org/10.1007/s10156-004-0315-5.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

10

Matthay, Michael A. "Pathophysiology of Pulmonary Edema". Clinics in Chest Medicine 6, n.º 3 (septiembre de 1985): 301–14. http://dx.doi.org/10.1016/s0272-5231(21)00366-x.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

11

Stroncek, David. "TRALI Pathophysiology." Blood 114, n.º 22 (20 de noviembre de 2009): SCI—48—SCI—48. http://dx.doi.org/10.1182/blood.v114.22.sci-48.sci-48.

Texto completo

Resumen

Abstract Abstract SCI-48 Transfusion related acute lung injury (TRALI) is clinically defined as the new onset of acute lung injury within 6 hours of a transfusion. In TRALI a transfusion activates neutrophils leading to pulmonary leukostasis, endothelial damage, capillary leak and pulmonary edema. A number of elements (bioactive lipids, sCD40L, and leukocyte antibodies) found in blood products can active neutrophils and are risk factors for TRALI. Bioactive lipids and sCD40L accumulate in both stored red cell and platelet components. Leukocyte antibodies are most often found in blood components collected from women alloimmunized during pregnancy. A number of animal and in vitro models have shown that neutrophils activated by leukocyte antibodies cause pulmonary leukostatsis, endothelial damage and capillary leak. Far more blood components contain these TRALI factors than cause TRALI suggesting that additional patient, clinical, or blood component factors are required for the development of TRALI. For example, neutrophil-specific antibodies cause reactions in, at most, 25% of transfusion recipients. Animal models and in vitro studies have found that blood component factors are more likely to induce lung injury if the neutrophils and/or pulmonary endothelial cells are primed or activated. Endothelial cells can be primed by endotoxin and neutrophils can be primed by bioactive lipids and sCD40L. The priming of neutrophils and /or endothelium results in the tight adhesion of neutrophils to endothelial cells and enhances endothelial cell injury Between neutrophil and HLA Class I and II antibodies, neutrophil antibodies are most potent at initiating TRALI and HLA Class I antibodies are least potent. HLA Class I antigens are expressed by platelets, lymphocytes, monocytes and soluble HLA Class I antigens are present in plasma. These sources of Class I antigens likely compete with neutrophils for transfused Class I antibodies and may render them less effective at initiating TRALI than neutrophil-specific or HLA Class II antibodies. Some evidence suggests that HLA Class I antibodies induce TRALI by binding to pulmonary endothelium and activating neutrophils through their Fc portion. Class II antibodies may initiate TRALI by binding to monocytes and stimulating cytokine release. In summary, TRALI is the result of patient and blood component factors which lead to neutrophil activation and endothelial cell damage and capillary leak. Most cases likely require the confluence of multiple factors to form a “perfect inflammatory storm” which leads to significant lung injury. Disclosures No relevant conflicts of interest to declare.

Los estilos APA, Harvard, Vancouver, ISO, etc.

12

Brudno, D. Spencer. "Pulmonary Vascular Physiology and Pathophysiology". Journal of Asthma 27, n.º 6 (enero de 1990): 413–14. http://dx.doi.org/10.3109/02770909009073361.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

13

Kulik, Thomas J. "Pathophysiology of acute pulmonary vasoconstriction". Pediatric Critical Care Medicine 11 (marzo de 2010): S10—S14. http://dx.doi.org/10.1097/pcc.0b013e3181c766c6.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

14

Dietz, Niki M. "Pathophysiology of Postpneumonectomy Pulmonary Edema". Seminars in Cardiothoracic and Vascular Anesthesia 4, n.º 1 (marzo de 2000): 31–35. http://dx.doi.org/10.1177/108925320000400105.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

15

Jain, Suma, Hector Ventura y Ben deBoisblanc. "Pathophysiology of Pulmonary Arterial Hypertension". Seminars in Cardiothoracic and Vascular Anesthesia 11, n.º 2 (junio de 2007): 104–9. http://dx.doi.org/10.1177/1089253207301732.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

16

Plovsing, Ronni R. y Ronan M. G. Berg. "Pulmonary Pathophysiology in Another Galaxy". Anesthesiology 120, n.º 1 (1 de enero de 2014): 230–32. http://dx.doi.org/10.1097/aln.0b013e31829c2dfb.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

17

Mason, Carol M., Warren R. Summer y Steve Nelson. "Pathophysiology of pulmonary defense mechanisms". Journal of Critical Care 7, n.º 1 (marzo de 1992): 42–46. http://dx.doi.org/10.1016/0883-9441(92)90007-t.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

18

Genofre, Eduardo Henrique, Francisco S. Vargas, Lisete R. Teixeira, Marcelo Alexandre Costa Vaz y Evaldo Marchi. "Reexpansion pulmonary edema". Jornal de Pneumologia 29, n.º 2 (abril de 2003): 101–6. http://dx.doi.org/10.1590/s0102-35862003000200010.

Texto completo

Resumen

Reexpansion pulmonary edema (RPE) is a rare, but frequently lethal, clinical condition. The precise pathophysiologic abnormalities associated with this disorder are still unknown, though decreased pulmonary surfactant levels and a pro-inflammatory status are putative mechanisms. Early diagnosis is crucial, since prognosis depends on early recognition and prompt treatment. Considering the high mortality rates related to RPE, preventive measures are still the best available strategy for patient handling. This review provides a brief overview of the pathophysiology, diagnosis, treatment, and prevention of RPE, with practical recommendations for adequate intervention.

Los estilos APA, Harvard, Vancouver, ISO, etc.

19

Crausman, R. S., C. A. Jennings, R. M. Tuder, L. M. Ackerson, C. G. Irvin y T. E. King. "Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology." American Journal of Respiratory and Critical Care Medicine 153, n.º 1 (enero de 1996): 426–35. http://dx.doi.org/10.1164/ajrccm.153.1.8542154.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

20

West, John B. "Internet-based course on pulmonary pathophysiology". Advances in Physiology Education 36, n.º 1 (marzo de 2012): 1–2. http://dx.doi.org/10.1152/advan.00125.2011.

Texto completo

Resumen

A course of seven video lectures on pulmonary pathophysiology has been placed on the internet. This is a companion to the course on respiratory physiology available at http://meded.ucsd.edu/ifp/jwest/ . That course dealt with normal respiratory physiology, and the new lectures are about the function of the diseased lung. The topics covered include pulmonary function tests, chronic obstructive pulmonary disease, asthma and localized airway obstruction, restrictive lung diseases, pulmonary vascular diseases, environmental or industrial lung diseases (with a short section on neoplastic and infectious diseases), and respiratory failure. Although it could be argued that PhD physiologists do not have a responsibility for teaching pathophysiology, collaborative teaching has become increasingly common in medical schools where, for example, a pulmonary block includes both normal respiratory physiology and some pulmonary pathophysiology. It is hoped that these lectures will be useful to physiologists in that setting.

Los estilos APA, Harvard, Vancouver, ISO, etc.

21

Jonathan, Steven, Triya Damayanti y Budhi Antariksa. "Pathophysiology of Emphysema". Jurnal Respirologi Indonesia 39, n.º 1 (2 de enero de 2019): 60–69. http://dx.doi.org/10.36497/jri.v39i1.43.

Texto completo

Resumen

Pulmonary emphysema is part of pathological condition in chronic obstructive pulmonary disease (COPD) which is characterized by lung parenchymal destruction. Morphology classification of emphysema had been made according to histologic structure in pathology. There were some causes known to be the culprit of emphysema; one that caught most attention is protease-antiprotease activity from cigarette smoke exposure. Destructive effect of emphysema gives disturbance of lung function in expiration (obstruction). The primary mechanism is elastic recoil reduction which causes air trapping, lung volume increase, lung compliance increase and airways that is susceptible to collapse. Hyperinflation in emphysema causes some disadvantages which complicate inspiration and give a dyspnea sensation. Equal pressure point drop in emphysema happens because of elastic recoil reduction. This drop may cause early airway closure. (J Respir Indo 2019; 39(1): 60-9)

Los estilos APA, Harvard, Vancouver, ISO, etc.

22

Humbert, M. "Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology". European Respiratory Review 19, n.º 115 (28 de febrero de 2010): 59–63. http://dx.doi.org/10.1183/09059180.00007309.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

23

Lee, Sang-Do. "Pathophysiology of Chronic Obstructive Pulmonary Disease". Journal of the Korean Medical Association 49, n.º 4 (2006): 305. http://dx.doi.org/10.5124/jkma.2006.49.4.305.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

24

Milic-Emili, Joseph, Matteo Pecchiari y Edgardo D'Angelo. "Pathophysiology of Chronic Obstructive Pulmonary Disease". Current Respiratory Medicine Reviews 4, n.º 4 (1 de noviembre de 2008): 250–57. http://dx.doi.org/10.2174/157339808786263842.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

25

Lan, Norris, Benjamin Massam, Sandeep Kulkarni y Chim Lang. "Pulmonary Arterial Hypertension: Pathophysiology and Treatment". Diseases 6, n.º 2 (16 de mayo de 2018): 38. http://dx.doi.org/10.3390/diseases6020038.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

26

Kim, Won Dong. "Pathophysiology of Chronic Obstructive Pulmonary Disease". Tuberculosis and Respiratory Diseases 41, n.º 5 (1994): 445. http://dx.doi.org/10.4046/trd.1994.41.5.445.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

27

Kim, Hyun Kuk y Sang-Do Lee. "Pathophysiology of Chronic Obstructive Pulmonary Disease". Tuberculosis and Respiratory Diseases 59, n.º 1 (2005): 5. http://dx.doi.org/10.4046/trd.2005.59.1.5.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

28

Lynne-Davies, Patricia. "PULMONARY PATHOPHYSIOLOGY—THE ESSENTIALS, 3rd ed". Chest 92, n.º 4 (octubre de 1987): 24. http://dx.doi.org/10.1016/s0012-3692(16)31273-9.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

29

Haas, François, Randi Fain, John Salazar-Schicchi y Kenneth Axen. "Pathophysiology of Chronic Obstructive Pulmonary Disease". Physical Medicine and Rehabilitation Clinics of North America 7, n.º 2 (mayo de 1996): 205–21. http://dx.doi.org/10.1016/s1047-9651(18)30393-0.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

30

Oliveira, Aline C., Elaine M. Richards y Mohan K. Raizada. "Pulmonary hypertension: Pathophysiology beyond the lung". Pharmacological Research 151 (enero de 2020): 104518. http://dx.doi.org/10.1016/j.phrs.2019.104518.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

31

O'Donnell, Christopher P., Fernando Holguin y Anne E. Dixon. "Pulmonary physiology and pathophysiology in obesity". Journal of Applied Physiology 108, n.º 1 (enero de 2010): 197–98. http://dx.doi.org/10.1152/japplphysiol.01208.2009.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

32

NAGAI, SONOKO y TAKATERU IZUMI. "Pulmonary Sarcoidosis: Population Differences and Pathophysiology". Southern Medical Journal 88, n.º 10 (octubre de 1995): 1001–10. http://dx.doi.org/10.1097/00007611-199510000-00002.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

33

Sysol, J. R. y R. F. Machado. "Classification and pathophysiology of pulmonary hypertension". Continuing Cardiology Education 4, n.º 1 (junio de 2018): 2–12. http://dx.doi.org/10.1002/cce2.71.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

34

Gonzalez, Norberto C. "Pulmonary Pathophysiology: The Essentials, 5th Edition". Medicine & Science in Sports & Exercise 31, n.º 1 (enero de 1999): 193–94. http://dx.doi.org/10.1097/00005768-199901000-00043.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

35

Thurlbeck, William M. "Pathophysiology of Chronic Obstructive Pulmonary Disease". Clinics in Chest Medicine 11, n.º 3 (septiembre de 1990): 389–403. http://dx.doi.org/10.1016/s0272-5231(21)00708-5.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

36

Simonneau, Gérald, Adam Torbicki, Peter Dorfmüller y Nick Kim. "The pathophysiology of chronic thromboembolic pulmonary hypertension". European Respiratory Review 26, n.º 143 (29 de marzo de 2017): 160112. http://dx.doi.org/10.1183/16000617.0112-2016.

Texto completo

Resumen

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, progressive pulmonary vascular disease that is usually a consequence of prior acute pulmonary embolism. CTEPH usually begins with persistent obstruction of large and/or middle-sized pulmonary arteries by organised thrombi. Failure of thrombi to resolve may be related to abnormal fibrinolysis or underlying haematological or autoimmune disorders. It is now known that small-vessel abnormalities also contribute to haemodynamic compromise, functional impairment and disease progression in CTEPH. Small-vessel disease can occur in obstructed areas, possibly triggered by unresolved thrombotic material, and downstream from occlusions, possibly because of excessive collateral blood supply from high-pressure bronchial and systemic arteries. The molecular processes underlying small-vessel disease are not completely understood and further research is needed in this area. The degree of small-vessel disease has a substantial impact on the severity of CTEPH and postsurgical outcomes. Interventional and medical treatment of CTEPH should aim to restore normal flow distribution within the pulmonary vasculature, unload the right ventricle and prevent or treat small-vessel disease. It requires early, reliable identification of patients with CTEPH and use of optimal treatment modalities in expert centres.

Los estilos APA, Harvard, Vancouver, ISO, etc.

37

Shenoy, Vikram, James M. Anton, Charles D. Collard y Sloan C. Youngblood. "Pulmonary Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension". Anesthesiology 120, n.º 5 (1 de mayo de 2014): 1255–61. http://dx.doi.org/10.1097/aln.0000000000000228.

Texto completo

Resumen

Abstract Pulmonary thromboendarterectomy is the most effective therapy for chronic thromboembolic pulmonary hypertension. The pathophysiology, anesthetic management, and perioperative outcomes of patients with chronic thromboembolic pulmonary hypertension undergoing pulmonary thromboendarterectomy are reviewed.

Los estilos APA, Harvard, Vancouver, ISO, etc.

38

Widdicombe, J. G. "Nasal pathophysiology". Respiratory Medicine 84 (noviembre de 1990): 3–10. http://dx.doi.org/10.1016/s0954-6111(08)80001-7.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

39

Kato, Hideyuki, Yaqin Yana Fu, Jiaquan Zhu, Lixing Wang, Shabana Aafaqi, Otto Rahkonen, Cameron Slorach et al. "Pulmonary vein stenosis and the pathophysiology of “upstream” pulmonary veins". Journal of Thoracic and Cardiovascular Surgery 148, n.º 1 (julio de 2014): 245–53. http://dx.doi.org/10.1016/j.jtcvs.2013.08.046.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

40

Chuchalin, A. G. "Pulmonary oedema: physiology of lung circulation, pathophysiology of pulmonary oedema". PULMONOLOGIYA, n.º 4 (28 de agosto de 2005): 9–18. http://dx.doi.org/10.18093/0869-0189-2005-0-4-9-18.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

41

Amariei, Diana E., Neal Dodia, Janaki Deepak, Stella E. Hines, Jeffrey R. Galvin, Sergei P. Atamas y Nevins W. Todd. "Combined Pulmonary Fibrosis and Emphysema: Pulmonary Function Testing and a Pathophysiology Perspective". Medicina 55, n.º 9 (10 de septiembre de 2019): 580. http://dx.doi.org/10.3390/medicina55090580.

Texto completo

Resumen

Combined pulmonary fibrosis and emphysema (CPFE) has been increasingly recognized over the past 10–15 years as a clinical entity characterized by rather severe imaging and gas exchange abnormalities, but often only mild impairment in spirometric and lung volume indices. In this review, we explore the gas exchange and mechanical pathophysiologic abnormalities of pulmonary emphysema, pulmonary fibrosis, and combined emphysema and fibrosis with the goal of understanding how individual pathophysiologic observations in emphysema and fibrosis alone may impact clinical observations on pulmonary function testing (PFT) patterns in patients with CPFE. Lung elastance and lung compliance in patients with CPFE are likely intermediate between those of patients with emphysema and fibrosis alone, suggesting a counter-balancing effect of each individual process. The outcome of combined emphysema and fibrosis results in higher lung volumes overall on PFTs compared to patients with pulmonary fibrosis alone, and the forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio in CPFE patients is generally preserved despite the presence of emphysema on chest computed tomography (CT) imaging. Conversely, there appears to be an additive deleterious effect on gas exchange properties of the lungs, reflecting a loss of normally functioning alveolar capillary units and effective surface area available for gas exchange, and manifested by a uniformly observed severe reduction in the diffusing capacity for carbon monoxide (DLCO). Despite normal or only mildly impaired spirometric and lung volume indices, patients with CPFE are often severely functionally impaired with an overall rather poor prognosis. As chest CT imaging continues to be a frequent imaging modality in patients with cardiopulmonary disease, we expect that patients with a combination of pulmonary emphysema and pulmonary fibrosis will continue to be observed. Understanding the pathophysiology of this combined process and the abnormalities that manifest on PFT testing will likely be helpful to clinicians involved with the care of patients with CPFE.

Los estilos APA, Harvard, Vancouver, ISO, etc.

42

Tsuchiya, Nanae, Lindsay Griffin, Hidetake Yabuuchi, Satoshi Kawanami, Jintetsu Shinzato y Sadayuki Murayama. "Imaging findings of pulmonary edema: Part 1. Cardiogenic pulmonary edema and acute respiratory distress syndrome". Acta Radiologica 61, n.º 2 (21 de junio de 2019): 184–94. http://dx.doi.org/10.1177/0284185119857433.

Texto completo

Resumen

Pulmonary edema has many causes; differentiating between these conditions is important. The purpose of this review article is to describe the pathophysiology of pulmonary edema, thereby explaining the imaging findings that differentiate between etiologies. Chest computed tomography provides details on the physiological response and the changes in the anatomical structures of pulmonary edema. An understanding of the pathophysiology underlying the imaging findings facilitates the correct identification of the cause of pulmonary edema.

Los estilos APA, Harvard, Vancouver, ISO, etc.

43

Nelson, Steve, Carol M. Mason, Jay Kolls y Warren R. Summer. "PATHOPHYSIOLOGY OF PNEUMONIA". Clinics in Chest Medicine 16, n.º 1 (marzo de 1995): 1–12. http://dx.doi.org/10.1016/s0272-5231(21)00975-8.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

44

McCool, F. Dennis y David E. Leith. "Pathophysiology of Cough". Clinics in Chest Medicine 8, n.º 2 (junio de 1987): 189–95. http://dx.doi.org/10.1016/s0272-5231(21)01014-5.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

45

Grissom, Colin K. y Mark R. Elstad. "The pathophysiology of high altitude pulmonary edema". Wilderness & Environmental Medicine 10, n.º 2 (junio de 1999): 88–92. http://dx.doi.org/10.1580/1080-6032(1999)010[0088:tpohap]2.3.co;2.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

46

Browne, George W. "Pathophysiology of pulmonary complications of acute pancreatitis". World Journal of Gastroenterology 12, n.º 44 (2006): 7087. http://dx.doi.org/10.3748/wjg.v12.i44.7087.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

47

Rubin, Lewis J. "Pathology and pathophysiology of primary pulmonary hypertension". American Journal of Cardiology 75, n.º 3 (enero de 1995): 51A—54A. http://dx.doi.org/10.1016/s0002-9149(99)80383-x.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

48

Qureshi, Amna Zafar y Robert M. R. Tulloh. "Paediatric pulmonary hypertension: aetiology, pathophysiology and treatment". Paediatrics and Child Health 27, n.º 2 (febrero de 2017): 50–57. http://dx.doi.org/10.1016/j.paed.2016.10.001.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

49

Bärtsch, P. "High-altitude pulmonary oedema: pathophysiology and treatment". European Journal of Anaesthesiology 17, Supplement 20 (2000): 12. http://dx.doi.org/10.1097/00003643-200000003-00023.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

50

Davis, Pamela. "Pathophysiology of Pulmonary Disease in Cystic Fibrosis". Seminars in Respiratory and Critical Care Medicine 6, n.º 04 (abril de 1985): 261–70. http://dx.doi.org/10.1055/s-2007-1011505.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Artículos de revistas sobre el tema "Pulmonary Pathophysiology"

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros